Your browser doesn't support javascript.
loading
Severe Phenotype in Patients with Large Deletions of NF1.
Pacot, Laurence; Vidaud, Dominique; Sabbagh, Audrey; Laurendeau, Ingrid; Briand-Suleau, Audrey; Coustier, Audrey; Maillard, Théodora; Barbance, Cécile; Morice-Picard, Fanny; Sigaudy, Sabine; Glazunova, Olga O; Damaj, Lena; Layet, Valérie; Quelin, Chloé; Gilbert-Dussardier, Brigitte; Audic, Frédérique; Dollfus, Hélène; Guerrot, Anne-Marie; Lespinasse, James; Julia, Sophie; Vantyghem, Marie-Christine; Drouard, Magali; Lackmy, Marilyn; Leheup, Bruno; Alembik, Yves; Lemaire, Alexia; Nitschké, Patrick; Petit, Florence; Dieux Coeslier, Anne; Mutez, Eugénie; Taieb, Alain; Fradin, Mélanie; Capri, Yline; Nasser, Hala; Ruaud, Lyse; Dauriat, Benjamin; Bourthoumieu, Sylvie; Geneviève, David; Audebert-Bellanger, Séverine; Nizon, Mathilde; Stoeva, Radka; Hickman, Geoffroy; Nicolas, Gaël; Mazereeuw-Hautier, Juliette; Jannic, Arnaud; Ferkal, Salah; Parfait, Béatrice; Vidaud, Michel; Wolkenstein, Pierre; Pasmant, Eric.
Affiliation
  • Pacot L; Service de Génétique et Biologie Moléculaires, Hôpital Cochin, DMU BioPhyGen, Assistance Publique-Hôpitaux de Paris, AP-HP, Centre-Université de Paris, F-75014 Paris, France.
  • Vidaud D; Inserm U1016-CNRS UMR8104, Institut Cochin, Université de Paris, CARPEM, F-75014 Paris, France.
  • Sabbagh A; Service de Génétique et Biologie Moléculaires, Hôpital Cochin, DMU BioPhyGen, Assistance Publique-Hôpitaux de Paris, AP-HP, Centre-Université de Paris, F-75014 Paris, France.
  • Laurendeau I; Inserm U1016-CNRS UMR8104, Institut Cochin, Université de Paris, CARPEM, F-75014 Paris, France.
  • Briand-Suleau A; UMR 261, Laboratoire MERIT, IRD, Faculté de Pharmacie de Paris, Université de Paris, F-75006 Paris, France.
  • Coustier A; Inserm U1016-CNRS UMR8104, Institut Cochin, Université de Paris, CARPEM, F-75014 Paris, France.
  • Maillard T; Service de Génétique et Biologie Moléculaires, Hôpital Cochin, DMU BioPhyGen, Assistance Publique-Hôpitaux de Paris, AP-HP, Centre-Université de Paris, F-75014 Paris, France.
  • Barbance C; Inserm U1016-CNRS UMR8104, Institut Cochin, Université de Paris, CARPEM, F-75014 Paris, France.
  • Morice-Picard F; Service de Génétique et Biologie Moléculaires, Hôpital Cochin, DMU BioPhyGen, Assistance Publique-Hôpitaux de Paris, AP-HP, Centre-Université de Paris, F-75014 Paris, France.
  • Sigaudy S; Service de Génétique et Biologie Moléculaires, Hôpital Cochin, DMU BioPhyGen, Assistance Publique-Hôpitaux de Paris, AP-HP, Centre-Université de Paris, F-75014 Paris, France.
  • Glazunova OO; Service de Génétique et Biologie Moléculaires, Hôpital Cochin, DMU BioPhyGen, Assistance Publique-Hôpitaux de Paris, AP-HP, Centre-Université de Paris, F-75014 Paris, France.
  • Damaj L; Inserm U1211, Service de Génétique Médicale, CHU de Bordeaux, F-33000 Bordeaux, France.
  • Layet V; Department of Medical Genetics, Children's Hospital La Timone, Assistance Publique des Hôpitaux de Marseille, F-13000 Marseille, France.
  • Quelin C; Centre de Référence des Anomalies du Développement et Syndromes Malformatifs (UF 2970), CHU Timone, Assistance Publique des Hôpitaux de Marseille, F-13000 Marseille, France.
  • Gilbert-Dussardier B; Department of Pediatrics, Competence Center of Inherited Metabolic Disorders, Rennes Hospital, F-35000 Rennes, France.
  • Audic F; Consultations de Génétique, Groupe Hospitalier du Havre, F-76600 Le Havre, France.
  • Dollfus H; Service de Génétique Clinique, CLAD Ouest, CHU Rennes, Hôpital Sud, F-35000 Rennes, France.
  • Guerrot AM; Service de Génétique, CHU de Poitiers, F-86000 Poitiers, France.
  • Lespinasse J; Service de Neurologie Pédiatrique, CHU Timone Enfants, F-13000 Marseille, France.
  • Julia S; Centre de Référence Pour les Affections Rares en Génétique Ophtalmologique, CARGO, Filière SENSGENE, Hôpitaux Universitaires de Strasbourg, F-67000 Strasbourg, France.
  • Vantyghem MC; Medical Genetics Laboratory, INSERM U1112, Institute of Medical Genetics of Alsace, Strasbourg Medical School, University of Strasbourg, F-67000 Strasbourg, France.
  • Drouard M; Service de Génétique Clinique, CHU de Rouen, F-76000 Rouen, France.
  • Lackmy M; Service de Génétique Clinique, CH de Chambéry, F-73000 Chambéry, France.
  • Leheup B; Service de Génétique Médicale, CHU de Toulouse, Hôpital Purpan, F-31000 Toulouse, France.
  • Alembik Y; Endocrinology, Diabetology, Metabolism and Nutrition Department, Inserm 1190, Lille University Hospital EGID, F-59000 Lille, France.
  • Lemaire A; Dermatology Department, CHU Lille, University of Lille, F-59000 Lille, France.
  • Nitschké P; Unité de Génétique Clinique, Centre de Compétences Maladies Rares Anomalies du Développement, CHRU de Pointe à Pitre, F-97110 Guadeloupe, France.
  • Petit F; Service de Génétique Médicale, Hôpitaux de Brabois, CHRU de Nancy, F-54500 Vandoeuvre-lès-Nancy, France.
  • Dieux Coeslier A; Department of Medical Genetics, Strasbourg-Hautepierre Hospital, F-67000 Strasbourg, France.
  • Mutez E; Department of Medical Genetics, Strasbourg-Hautepierre Hospital, F-67000 Strasbourg, France.
  • Taieb A; Bioinformatics Platform, Imagine Institute, INSERM UMR 1163, Université de Paris, F-75015 Paris, France.
  • Fradin M; CHU Lille, Clinique de Génétique, Centre de Référence Anomalies du Développement, F-59000 Lille, France.
  • Capri Y; CHU Lille, Clinique de Génétique, Centre de Référence Anomalies du Développement, F-59000 Lille, France.
  • Nasser H; Lille University, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, F-59000 Lille, France.
  • Ruaud L; Department of Dermatology and Pediatric Dermatology, Bordeaux University Hospital, F-33000 Bordeaux, France.
  • Dauriat B; Service de Génétique Clinique, CLAD Ouest, CHU Rennes, Hôpital Sud, F-35000 Rennes, France.
  • Bourthoumieu S; Département de Génétique, APHP Nord, Hôpital Robert Debré, F-75019 Paris, France.
  • Geneviève D; Département de Génétique, APHP Nord, Hôpital Robert Debré, F-75019 Paris, France.
  • Audebert-Bellanger S; Département de Génétique, APHP Nord, Hôpital Robert Debré, F-75019 Paris, France.
  • Nizon M; UMR 1141, NEURODIDEROT, INSERM, Université de Paris, F-75019 Paris, France.
  • Stoeva R; Department of Cytogenetics and Clinical Genetics, Limoges University Hospital, F-87000 Limoges, France.
  • Hickman G; Service de Cytogénétique et Génétique Médicale, CHU Limoges, F-87000 Limoges, France.
  • Nicolas G; Department of Genetics, Arnaud de Villeneuve University Hospital, F-34000 Montpellier, France.
  • Mazereeuw-Hautier J; Département de Génétique Médicale et Biologie de la Reproduction, CHU Brest, Hôpital Morvan, F-29200 Brest, France.
  • Jannic A; Genetic Medical Department, CHU Nantes, F-44000 Nantes, France.
  • Ferkal S; Service de Cytogénétique, Centre Hospitalier Universitaire du Mans, F-72000 Le Mans, France.
  • Parfait B; Department of Dermatology, Reference Center for Rare Skin Diseases MAGEC, Saint Louis Hospital AP-HP, F-75010 Paris, France.
  • Vidaud M; Department of Genetics, FHU G4 Génomique, Normandie University, UNIROUEN, CHU Rouen, Inserm U1245, F-76000 Rouen, France.
  • Members Of The Nf France Network; Département de Dermatologie, Centre de Référence des Maladies Rares de la Peau, CHU de Toulouse, F-31000 Toulouse, France.
  • Wolkenstein P; Département de Dermatologie, AP-HP and UPEC, Hôpital Henri-Mondor, F-94000 Créteil, France.
Cancers (Basel) ; 13(12)2021 Jun 13.
Article in En | MEDLINE | ID: mdl-34199217
ABSTRACT
Complete deletion of the NF1 gene is identified in 5-10% of patients with neurofibromatosis type 1 (NF1). Several studies have previously described particularly severe forms of the disease in NF1 patients with deletion of the NF1 locus, but comprehensive descriptions of large cohorts are still missing to fully characterize this contiguous gene syndrome. NF1-deleted patients were enrolled and phenotypically characterized with a standardized questionnaire between 2005 and 2020 from a large French NF1 cohort. Statistical analyses for main NF1-associated symptoms were performed versus an NF1 reference population. A deletion of the NF1 gene was detected in 4% (139/3479) of molecularly confirmed NF1 index cases. The median age of the group at clinical investigations was 21 years old. A comprehensive clinical assessment showed that 93% (116/126) of NF1-deleted patients fulfilled the NIH criteria for NF1. More than half had café-au-lait spots, skinfold freckling, Lisch nodules, neurofibromas, neurological abnormalities, and cognitive impairment or learning disabilities. Comparison with previously described "classic" NF1 cohorts showed a significantly higher proportion of symptomatic spinal neurofibromas, dysmorphism, learning disabilities, malignancies, and skeletal and cardiovascular abnormalities in the NF1-deleted group. We described the largest NF1-deleted cohort to date and clarified the more severe phenotype observed in these patients.
Key words

Full text: 1 Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Cancers (Basel) Year: 2021 Type: Article Affiliation country: France

Full text: 1 Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Cancers (Basel) Year: 2021 Type: Article Affiliation country: France